EC launches innovation partnerships to foster sustainable research
02.03.2012 - With three new Innovation Partnerships, the European Commission (EC) intends to eliminate weaknesses, bottlenecks and obstacles in the European research and innovation system.
The key challenges to be met are the supply of raw materials, sustainable agriculture, and active and healthy ageing. It’s the Commission’s view that all three require a more concerted innovation effort across the public and private sector, in order to improve quality of life and position Europe as a global leader. The agricultural productivity and sustainability partnership aims at the reversal of the recent trend of diminishing productivity gains and targets to improve soil quality to a satisfactory level by 2020. In order to increase innovation supporting exploration, extraction and processing of raw materials, the Commission launched the raw materials partnership. The project is set to improve recycling of electronic equipment and other waste and calls for the development of substitutes for critical raw materials. Finally, the European Innovation Partnership on active and healthy ageing seeks solutions for the demographic change in Europe. The number of European citizens aged 65 and over will double over the next 50 years. This poses the European care and social systems to a challenge and calls for redesigning these systems in the interest of patients, healthcare systems and the innovative industry.
23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.
19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.
17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).
15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).
09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.
08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.
01.08.2016 Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome.
FILTRODISC™ BIO SD is a filtration system which removes particles (e.g. cells, bacteria, yeast), impurities (e.g. HCP, DNA) and other turbid matter from process liquids (e.g. fermentation broths). more